Deep TMS News - Get The Latest News On BrainsWay's Deep TMS

News & Events

March 1, 2022

BrainsWay to Present at the 32nd Annual Oppenheimer Healthcare Conference

BURLINGTON, Mass. and JERUSALEM, March 01, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

February 28, 2022

BrainsWay to Report Fourth Quarter and Full Year 2021 Financial Results on March 9, 2022

BURLINGTON, Mass. and JERUSALEM, Feb. 28, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

February 23, 2022

BrainsWay Announces Publication of Results Demonstrating Efficacy of Deep TMS™ in Treating Anxiety Symptoms Comorbid to Depression

Results Distinguish Deep TMS as More Effective in Subjects with Higher Anxiety Symptoms, Long Considered...

February 1, 2022

BrainsWay to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

BURLINGTON, Mass. and JERUSALEM, February 1, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

January 31, 2022

BrainsWay Announces Final Local Coverage Determination Issued by Regional Medicare Administrative Contractor Palmetto GBA Providing Coverage of Deep TMS™ for the Treatment of OCD

Palmetto GBA Covers Medicare Patients in Seven States BURLINGTON, Mass. and JERUSALEM, January 31, 2022...

January 26, 2022

BrainsWay Announces Addition of Markus Heilig, M.D., Ph.D., to Scientific Advisory Board

World-Renowned Specialist in Addiction and Anxiety Treatment Joins Premier Group of Researchers and Clinicians...

January 12, 2022

BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System

Positive Data Support the Durability and Cost-Effectiveness of Deep TMS as a Treatment for Obsessive-Compulsive...

December 9, 2021

BrainsWay Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects

Randomized, Placebo-Controlled, Double-Blind Pilot Study Evaluated Deep TMS Treatment in Reducing Alcohol...

November 30, 2021

BrainsWay to Present at the Sidoti December Micro-Cap Investor Conference

BURLINGTON, Mass. and JERUSALEM, November 30, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ &...

November 17, 2021

BrainsWay Reports Third Quarter 2021 Financial Results and Operational Highlights

Revenue Growth of 34% Year-over-Year in Q3 2021 Received Regulatory Clearance for Deep TMS™ System...

November 3, 2021

BrainsWay to Report Third Quarter 2021 Financial Results on November 17, 2021

BURLINGTON, Mass. and JERUSALEM, Nov. 03, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

October 12, 2021

BrainsWay Announces Prominent Addition to Scientific Advisory Board

Zafiris Daskalakis, MD, PhD to Bring Extensive Research and Clinical Expertise to Assist in Guiding Growth...

September 30, 2021

BrainsWay Announces Data Published in World Psychiatry on Deep Transcranial Magnetic Stimulation (Deep TMS™) for Smoking Addiction

Evidence Supports Use of Deep TMS as a Safe and Effective Treatment for Smoking Addiction BURLINGTON,...

September 9, 2021

BrainsWay to Participate in Two Upcoming Investor Conferences in 2021

BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

August 30, 2021

BrainsWay to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass. and JERUSALEM, August 30, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

August 18, 2021

FDA Clears BrainsWay Deep TMS™ System for Decreasing Anxiety Symptoms in Depressed Patients

Expanded Depression Indication Further Demonstrates Company’s Leadership Position BURLINGTON, Mass....

August 17, 2021

BrainsWay Hosting Key Opinion Leader Webinar on its Deep TMS™ Therapy for Treating Mental Health Disorders

BURLINGTON, MA. and JERUSALEM, August 17, 2021 – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”...

August 11, 2021

BrainsWay Reports Second Quarter 2021 Financial Results and Operational Highlights

Strong Revenue Growth of 45% Year-over-Year in Q2 2021 Gained Meaningful Traction in Reimbursement for...